1. Home
  2. CCBG vs NGNE Comparison

CCBG vs NGNE Comparison

Compare CCBG & NGNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Capital City Bank Group

CCBG

Capital City Bank Group

N/A

Current Price

$49.57

Market Cap

828.1M

Sector

Finance

ML Signal

N/A

Logo Neurogene Inc.

NGNE

Neurogene Inc.

N/A

Current Price

$22.85

Market Cap

744.9M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
CCBG
NGNE
Founded
1895
2003
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
828.1M
744.9M
IPO Year
1994
2014

Fundamental Metrics

Financial Performance
Metric
CCBG
NGNE
Price
$49.57
$22.85
Analyst Decision
Hold
Strong Buy
Analyst Count
3
10
Target Price
$53.83
★ $77.63
AVG Volume (30 Days)
61.4K
★ 261.1K
Earning Date
10-20-2026
11-09-2026
Dividend Yield
★ 2.17%
N/A
EPS Growth
★ 15.38
0.93
EPS
★ 2.86
N/A
Revenue
N/A
N/A
Revenue This Year
$1.18
N/A
Revenue Next Year
$3.29
N/A
P/E Ratio
$17.49
★ N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$39.26
$15.93
52 Week High
$53.60
$43.66

Technical Indicators

Market Signals
Indicator
CCBG
NGNE
Relative Strength Index (RSI) 43.16 37.26
Support Level $47.63 $21.05
Resistance Level $51.93 $23.35
Average True Range (ATR) 1.16 1.95
MACD -0.19 -0.21
Stochastic Oscillator 19.19 5.99

Price Performance

Historical Comparison
CCBG
NGNE

About CCBG Capital City Bank Group

Capital City Bank Group Inc is a United States-based group engaged in Banking services, Trust and asset management services, and Brokerage services. The company operates in one segment with two principal services: Banking Services and Wealth Management Services. It offers retail and commercial banking business in the form of traditional deposit and credit services, asset management, trust, mortgage banking, merchant services, bank cards, data processing, and securities brokerage services, among others, through its banking offices in Florida, Georgia, and Alabama.

About NGNE Neurogene Inc.

Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACT(Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.

Share on Social Networks: